{
  "url": "https://www.law.cornell.edu/regulations/new-york/21-NYCRR-4255.3",
  "title": "N.Y. Comp. Codes R. & Regs. Tit. 21 ยง 4255.3 - New York Fund for Innovation in Research and Scientific Talent (NYFIRST) Program",
  "content": "N.Y. Comp. Codes R. & Regs. Tit. 21 ยง 4255.3 - New York Fund for Innovation in Research and Scientific Talent (NYFIRST) Program\n\nState Regulations\n(a) Authority\nand purpose. The New York State Urban Development Corporation hereby\nestablishes the New York Fund for Innovation in Research and Scientific Talent\n(NYFIRST) Program as a component of the Life Sciences Initiatives Program. NYFIRST is intended to encourage the recruitment and retention of exceptional\nlife science researchers and world-class talent at the state's medical schools\nto accelerate translational research. The recruited or retained researchers\nwill demonstrate proven scientific accomplishments and a history of\nentrepreneurship and grant funding. NYFIRST funds will be used to support the\nestablishment or upgrading of laboratories for these researchers, for purchases\nof capital equipment and specialized supplies needed for their research, and as\nworking capital to cover costs of professional staff (including staff\nscientists, doctoral students/post-doctoral fellows, and technicians, but\nexcluding the recruited researcher) critical to the proposed research. The NYFIRST Program is intended to: (1)\nincrease the number of patent\napplications and patentable discoveries at medical schools and the number of\npatents from these schools; (2)\nincrease the recruitment/retention rate of medical school faculty focused on\ntranslational research; (3)\nenhance\nand expand the expertise, qualifications and capabilities residing within these\ninstitutions; and\n(4)\nincrease\n\nFederal and philanthropic funding, as well as venture capital funding, to\nmedical schools awarded NYFIRST grants. (b) Definitions. For the purposes of this section, the terms below shall have\nthe following meaning: (1)\n\nApplicant\nor\neligible applicant\nshall mean a\nmedical school within the State that applies for NYFIRST assistance. (2)\n\nCorporation\nor\nESD\nshall mean the New York State Urban Development\n\nCorporation doing business as Empire State Development. (3)\n\nEligible project\nshall\nmean a project that meets the eligibility criteria set forth in subdivision (d)\nof this section. (4)\n\nFederal assistance\nshall mean funds available, other than by\nloan, from the Federal government, either directly, or through allocation by\nthe State for program purposes pursuant to any Federal law or\nprogram. (5)\n\nLife sciences\neconomic development benefits\nshall mean the creation, expansion, enhancement or acceleration of life sciences programs throughout the State that\nlead to: (i) the commercialization of life\nsciences in New York State; (ii)\nthe creation or retention of jobs in the life sciences industry employing full\ntime permanent employees; (iii)\nthe\npromotion of the life science ecosystem within a region of the State; (iv)\nnew patents in life science; (v) additional commercial laboratory space; or\n(vi)\nadditional venture capital\nmoney for life sciences entities in New York State. (6)\n\nMatch, matching, or\nmatching funds\nshall mean that portion of\nthe total cost of a project that the grantee must provide, pursuant to\nparagraph (c)(2) of this section. (7)\n\nMedical school\nshall\nmean a public or private medical school in New York State that is accredited by\nthe liaison committee on medical education or the commission on osteopathic\ncollege accreditation, or such medical school together with an affiliated\nentity, located in New York State. (8)\n\nPrincipal investigator\nshall mean the holder of an independent grant administered by a university and\nthe lead researcher for the grant project who makes the final decisions and\nsupervises funding and expenditures on a given research project. (9)\n\nProject\nshall mean the\nscope of activities supported by a NYFIRST Program grant and the grantee's\nmatching share. (10)\n\nReimbursable expenses\nshall mean approved costs incurred by\nthe NYFIRST grantee to perform the project. Reimbursable expenses must be\nincurred during the grant term. An item included as a match cannot also be\nincluded as a reimbursable expense. (11)\n\nSpecialized supplies\nshall mean consumables, including, but not limited to, antibodies, assay kits, proteins, reagents, enzymes, DNA/RNA and PCR products, nucleosides and\nnucleotides, specialized media, substrates and other bioproducts required to\nconduct the research specified. (12)\n\nTranslational research\nshall mean research that applies, or translates, existing knowledge about\nbiology into techniques and tools for treating human disease: translational\nresearch takes knowledge from bench to bedside. This differs from academic\nresearch, which is focused on careful study of a subject or field to discover\nfacts or principles that are added to the general body of scientific\nknowledge. (c) Available program assistance. (1)\n\nThe NYFIRST Program makes available financial assistance in the form of grants\nto applicants for eligible projects. The maximum grant amount for any eligible\nproject is $1 million. (2)\n\nMatching\nfunds. Grantees will be required to provide $2 of matching funds for every $1\nof NYFIRST Program assistance. The match is a non-reimbursable component of the\nproject's total cost and is reflective of the grantee's long-term commitment to\nthe project. (i) The match provided by the\ngrantee may be cash, including Federal assistance, or in-kind services. If\nin-kind services any match item may be donated by the grantee or reflect the\ngrantee's use for the project of such an item donated by a third party (such as\nindustry or alumni/ae). However, no financial assistance made available to the\ngrantee by the corporation or any other New York State agency or public\nauthority may be included as part of any program grantee's match. Nothing in\nthis subdivision shall prohibit the State University of New York or the City\n\nUniversity of New York from using a portion of their respective operating funds\nas match. (ii)\n\nItems eligible to be\napproved are matching funds directly related to the purpose of the project\nincluding, but not limited to: compensation for the recruited principal\ninvestigator meeting the eligibility criteria described in paragraph (d)(3) of\nthis section; financial support for research staff and graduate students who\nare members of the newly recruited principal investigator's team; relocation\nexpenses for the aforementioned principal investigator or associated team; other expenses as are necessary for recruitment purposes; the cost of preparing\nand equipping work space for the principal investigator or associated team; other expenses required to conduct the relevant research undertaken by the\nprincipal investigator or associated team such as laboratory supplies; and the\ncost of new faculty lines in research areas to complement the recruited\nprincipal investigator and his/her team. (iii)\n\nAll matching funds must be expended\nduring the program grant term and where practicable on a\npro\nrata\nbasis with program grant funding. (iv)\n\nAll items identified as matching funds\nwill be reviewed by the corporation, which will approve such matching funds as\nthe corporation may determine, in its sole discretion, to be reasonable as to\namount and relation to the project. (3)\n\nProgram grant funds will be disbursed on\na semiannual reimbursement basis. Grantees shall submit quarterly invoices\ntwice yearly with and supporting documentation satisfactory to the corporation, as work is performed and costs incurred. (d) Eligibility criteria. (1)\n\nProgram grants are intended to encourage\nthe recruitment and retention by the State's medical schools of exceptional\nlife science researchers and world-class talent focused on accelerating\ntranslational research. NYFIRST grants may be used to support the establishment\nor upgrading of laboratories for these researchers, for purchases of capital\nequipment and specialized supplies needed for their research, and as working\ncapital to cover costs of professional staff (including staff scientists, doctoral students/post-doctoral fellows, and technicians, but excluding the\nrecruited principal investigator) critical to the proposed research. (2)\nESD will make no more than one award per\napplicant per application cycle. (3)\n\nThe scientific talent recruited or\nretained as a principal investigator to head a laboratory must: (i) demonstrate a record of translational\nresearch with clear potential for commercialization; (ii)\ndemonstrate that the research to be\nundertaken focuses on the development of an innovative solution for an\nidentified healthcare-related problem, with the potential to result in\nsignificant life sciences economic development benefits in New York\n\nState; (iii)\ndemonstrate a history\nof entrepreneurship such as by patent applications, patent approvals and\ncommercialization of research and by success in obtaining funding; (iv)\nhave sufficient funding to support the\nproject being undertaken for three years; (v) be tenured or be on a tenure track and\nprovide sufficient documentation to ESD to corroborate such track; (vi)\nhire or retain (or cause to be hired or\nretained by the medical school) at least two scientists or doctoral\nstudents/post-doctoral fellows full-time (40hrs/week) or at least four\nscientists or doctoral students/post-doctoral fellows who each work a minimum\nof 20hrs/week; the scientists and post-doctoral fellows must be recruited from\noutside of New York State; and\n(vii)\nbe employed by an institution or\ncompany outside New York State at the time an offer of employment is made by\nthe applicant, or have a verifiable offer from an institution from another\nstate that would lead him/her to leave New York State. (See paragraph\n[e][2][ii] of this section.)\n(4)\n\nThe offer of employment to the principal\ninvestigator by the applicant must be made between the date of availability of\nthe NYFIRST application for a given application cycle and the application\ndeadline for that cycle. Acceptance of such offer also must occur between the\ndate of availability of the NYFIRST application for a given application cycle\nand the application deadline for that cycle. (5)\nA copy of the accepted employment offer\nmust be submitted with the NYFIRST application. (6)\n\nThe grant term is four years, and all\nexpenditures for which program funding is approved must be commenced and\ncompleted no more than four years from commencement of the grant. The\ncorporation, in its sole discretion, may terminate the program grant for any\neligible project that does not adhere to the timelines established in the grant\nagreement or otherwise fails to demonstrate satisfactory performance. (e) Application requirements, process and evaluation. (1)\n\nOn an\napplication provided by ESD, the applicant shall provide such information about\nthe applicant, the principal investigator and the project as ESD may require. The application shall highlight the following information relevant to the\nresearch being undertaken: unmet clinical need, market potential, and an\napproximate timeline and anticipated steps to market/clinical use. There are no\nrestrictions in terms of therapeutic area of research. The completed\napplication shall illustrate how the applicant has met the criteria established\nin paragraph (d)(3) of this section and also will include details regarding the\nfollowing: (i) therapeutic need for the\nresearch\ne.g., extent of the unmet need for therapeutics, diagnostics or other intellectual property; what alternatives are already\navailable, market size, and market environment; (ii)\nanticipated path to commercialization; key milestones to be met as this research moves toward\ncommercialization; (iii)\nuniqueness\nof the research and competitive edge; (iv)\nsummary of supporting proof of concept\ndata and other relevant research, and publications; (v) strength of principal investigator's\nintellectual property/entrepreneurial history and intellectual property\npotential and patent considerations of proposed research; (vi)\nproposed scope of work, timeline and the\nfeasibility of timeline; (vii)\nprofile(s) of the recruited or retained principal investigator and the proposed\nteam members; (viii)\nbudget; (ix)\ntotal amount of NIH\nand other funding that will accompany the recruited principal investigator as\nwell as his/her funding history; and\n(x) documentation establishing that the term\nof employment between the institution (the grantee) and the principal\ninvestigator, as well as each member of the team accompanying the principal\ninvestigator is, at a minimum, for a period coextensive with the grant\nterm. (2)\n\nThe\napplication must also be accompanied by: (i) a\nsigned statement of support of the proposed project executed by the chief\nexecutive officer or dean of the applicant medical school, and in a format\napproved by the corporation, recommending the application to the corporation\nand authorizing an official of the applicant institution to execute documents\nnecessary for the project; (ii)\na\ncopy of the dated and accepted offer letter by the principal investigator, indicating the specific position offered and tenure status and including\nagreement on anticipated commencement of employment. (Confidential information\nunrelated to the position, date of offer and signed acceptance may be redacted)\nor, in the case of retention of a principal investigator considering an offer\nfrom an institution outside of New York State, a signed statement by the chief\nexecutive officer or dean of the applicant medical school, verifying that the\nprincipal investigator had indicated his/her intention to relocate to another\ninstitution outside of New York State, with details regarding the potential\noffer, including position and salary, and that a counteroffer has been made and\naccepted. A copy of the counteroffer and of the acceptance of same must be\nprovided; (iii)\nverification that\nthe recruited principal investigator was employed at an institution from\noutside of New York State prior to receipt and acceptance of the offer letter; and\n(iv)\nsuch other information as\nthe corporation may require to implement this program. (3)\n\nTo the extent practicable, ESD will\nattempt to make awards to as many medical schools as possible within the State, assuming equivalent qualifying evaluation scores and taking into consideration\nregional balance, anticipated job creation and retention and economic\ndevelopment benefits. (f) Selection criteria/scoring. (1)\n\nApplications will be evaluated on the criteria detailed in subdivision (d) of\nthis section and the documentation provided pursuant to paragraph (e)(1) of\nthis section on a scale of one to five, where: 1 = does not meet qualification expectation; 3 = meets qualification expectations; and\n5 = exceeds qualification expectations. (2)\n\nSelection criteria will be weighted as\nfollows: Criteria Category\n\nWeight\n1. Unmet need\n30%\n2. Novelty & competitiveness of proposed\nsolution\n30%\n3. Preliminary/supporting data\n15%\n4. Strength of principal investigator's intellectual\nproperty history and patent potential of proposed research\n15%\n5. Feasibility of development\ntimeline\n10%\n(3)\n\nThe corporation intends to make program grant awards through a competitive\ngrant solicitation to qualifying applicants twice annually until the funds\nunder this program are fully committed. (4)\n\nFor each application cycle, the period\nbetween application availability and the application deadline shall be six\nmonths. (g) Eligible uses. (1)\n\nProgram\ngrants must be used for expenses directly related to the eligible project\nincluding but not limited to: (i) costs\nrelating to the design, acquisition, construction, reconstruction and\nrehabilitation of laboratory space; (ii)\ncapital equipment purchases; (iii)\nspecialized supplies purchases; and\n(iv)\nworking capital to cover\ncosts of professional staff critical to the research to be undertaken by the\nprincipal investigator (including staff scientists, postdoctoral fellows and\ntechnicians, but excluding the principal investigator). (2)\n\nThe corporation may determine not to\nreimburse eligible expenses if the award recipient fails to maintain its\nrequired level of match during a specific grant disbursement period. (3)\n\nProgram grants shall not duplicate\npayments received, or receivable, from other sources. (h) Reporting requirements. (1)\n\nThe corporation is required by statute to\nsubmit to the Governor, the temporary president of the New York State Senate, and the speaker of the New York State Assembly an annual report on the\noperations and accomplishments of the life sciences initiatives programs on or\nbefore October 1st annually. The report must include, but is not limited to, information and statistics detailing the economic impact of the activities\nundertaken with program funds; the number and amount of Federal funds procured\nafter an investment of program funds; jobs created and maintained after receipt\nof program funds; and the average salaries of such jobs created and\nmaintained. (2)\n\nThe corporation\nwill establish periodic reporting requirements for program grantees to provide\ninformation to the corporation so that the corporation may accomplish its\nstatutory reporting obligations. These reporting obligations may extend beyond\nthe completion of the project for a period of three years. (3)\n\nFailure by a grantee to provide the\nrequired information in a manner that is timely and otherwise satisfactory to\nthe corporation may subject the grant to full or partial recapture. Notes\nN.Y. Comp. Codes\nR. & Regs. Tit. 21\nยง\n4255.3\n\nAmended\n\nNew\n\nYork State Register May 22, 2019/Volume XLI, Issue 21, eff. 5/2/2019\n\nAmended\n\nNew\n\nYork State Register November 20, 2019/Volume XLI, Issue 47, eff. 11/20/2019\n\nThe amended version of this section by\n\nNew\n\nYork State Register December 22, 2021/Volume XLIII, Issue 51, eff. 12/22/2021\n\nState regulations are updated quarterly; we currently have two versions available. Below is a\ncomparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare. No prior version found.",
  "url_type": "regulation",
  "source_index": 11857
}